337 related articles for article (PubMed ID: 29881716)
1. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
2. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
3. The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.
Ahn A; Chatterjee A; Eccles MR
Mol Cancer Ther; 2017 Jun; 16(6):1002-1009. PubMed ID: 28576947
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
O'Connell MP; Marchbank K; Webster MR; Valiga AA; Kaur A; Vultur A; Li L; Herlyn M; Villanueva J; Liu Q; Yin X; Widura S; Nelson J; Ruiz N; Camilli TC; Indig FE; Flaherty KT; Wargo JA; Frederick DT; Cooper ZA; Nair S; Amaravadi RK; Schuchter LM; Karakousis GC; Xu W; Xu X; Weeraratna AT
Cancer Discov; 2013 Dec; 3(12):1378-93. PubMed ID: 24104062
[TBL] [Abstract][Full Text] [Related]
5. The MITF regulatory network in melanoma.
Chauhan JS; Hölzel M; Lambert JP; Buffa FM; Goding CR
Pigment Cell Melanoma Res; 2022 Sep; 35(5):517-533. PubMed ID: 35771179
[TBL] [Abstract][Full Text] [Related]
6. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.
Cheli Y; Giuliano S; Fenouille N; Allegra M; Hofman V; Hofman P; Bahadoran P; Lacour JP; Tartare-Deckert S; Bertolotto C; Ballotti R
Oncogene; 2012 May; 31(19):2461-70. PubMed ID: 21996743
[TBL] [Abstract][Full Text] [Related]
8. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M
Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871
[TBL] [Abstract][Full Text] [Related]
9. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
11. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
12. Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease.
Travnickova J; Wojciechowska S; Khamseh A; Gautier P; Brown DV; Lefevre T; Brombin A; Ewing A; Capper A; Spitzer M; Dilshat R; Semple CA; Mathers ME; Lister JA; Steingrimsson E; Voet T; Ponting CP; Patton EE
Cancer Res; 2019 Nov; 79(22):5769-5784. PubMed ID: 31582381
[TBL] [Abstract][Full Text] [Related]
13. Trametinib-Resistant Melanoma Cells Displaying MITF
Koziej P; Kluszczynska K; Hartman ML; Czyz M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
[TBL] [Abstract][Full Text] [Related]
14. Microenvironment-derived factors driving metastatic plasticity in melanoma.
Kim IS; Heilmann S; Kansler ER; Zhang Y; Zimmer M; Ratnakumar K; Bowman RL; Simon-Vermot T; Fennell M; Garippa R; Lu L; Lee W; Hollmann T; Xavier JB; White RM
Nat Commun; 2017 Feb; 8():14343. PubMed ID: 28181494
[TBL] [Abstract][Full Text] [Related]
15. Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity.
Vivas-García Y; Falletta P; Liebing J; Louphrasitthiphol P; Feng Y; Chauhan J; Scott DA; Glodde N; Chocarro-Calvo A; Bonham S; Osterman AL; Fischer R; Ronai Z; García-Jiménez C; Hölzel M; Goding CR
Mol Cell; 2020 Jan; 77(1):120-137.e9. PubMed ID: 31733993
[TBL] [Abstract][Full Text] [Related]
16. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
Wessely A; Steeb T; Berking C; Heppt MV
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
[TBL] [Abstract][Full Text] [Related]
17. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.
Hartman ML; Talar B; Noman MZ; Gajos-Michniewicz A; Chouaib S; Czyz M
PLoS One; 2014; 9(4):e95157. PubMed ID: 24733089
[TBL] [Abstract][Full Text] [Related]
19.
Ennen M; Keime C; Gambi G; Kieny A; Coassolo S; Thibault-Carpentier C; Margerin-Schaller F; Davidson G; Vagne C; Lipsker D; Davidson I
Clin Cancer Res; 2017 Nov; 23(22):7097-7107. PubMed ID: 28855355
[No Abstract] [Full Text] [Related]
20. The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Ballotti R; Cheli Y; Bertolotto C
Mol Cancer; 2020 Dec; 19(1):170. PubMed ID: 33276788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
